Global Breast Cancer Diagnostics Market Outlook to 2028

DUBLIN, September 16, 2021 / PRNewswire / – The “Global Breast Cancer Diagnostics Market Size, Share and Trend Analysis Report by Product (Platform Based, Instrument Based), By Type (Imaging , biopsy, genomic testing, blood tests), by application, by purpose -Use, by region and segment forecast, 2021-2028 “has been added to ResearchAndMarkets.com offer.

The global breast cancer diagnostics market size is expected to reach $ 6.8 billion by 2028. The market is expected to grow at a CAGR of 7.0% from 2021 to 2028.

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient callbacks. Rapid technological advancement is a major factor that is expected to drive the market over the next few years.

Companies adopt strategies that allow them to use their resources to help develop new products, as well as improve their supply chain. In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which is expected to help improve the company’s position and offerings in the market by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately $ 230 million. Biotheranostics is a provider of commercial stage molecular diagnostics for breast and metastatic cancers.

The increasing launch of predictive and companion diagnostic tests for breast cancer is expected to drive the market growth. Recent launches in the segment include BRACAnalysis CDx from Myriad Genetics, which received FDA approval in 2018 as a companion diagnostic for breast cancer. In May 2019, QIAGEN introduced the therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for PIQRAY, owned by Novartis, to guide treatment decisions based on tissue and fluid biopsy.

In January 2019, Fujifilm Holdings Corporation presented its tomosynthesis biopsy option for the ASPIRE Cristalle mammography system. This technique was supposed to allow doctors to detect breast cancers more effectively than others by providing an improved 3D image and digital mammography.

However, there are specific risk factors associated with these imaging procedures. They involve the administration of high doses of fluorescent and barium contrast agents, as well as radiation exposure in the case of imaging and endoscopy procedures, which can cause several side effects such as nausea or diarrhea. The risks of exposure to ionizing radiation associated with the use of CT, MRI and X-rays, as well as the use of radioactive tracer injections in PET, may limit the adoption of such screening procedures. Hence, factors like side effects of imaging pose a challenge for companies in this market.

Highlights of the Breast Cancer Diagnostics Market Report

  • Imaging segment held the largest share of revenue in 2020 and blood testing segment is expected to grow at the fastest rate
  • By product, the device-based products segment accounted for the largest share of revenue in 2020 due to government initiatives such as mandatory testing in developed countries such as the United States, Canada, and in the UK for women over 45, increasing the overall number of breast cancer tests and screenings
  • The platform-based product segment is expected to experience the fastest growth during the forecast period. These tests are primarily used to assess the effectiveness of chemotherapy and targeted therapy in women.
  • By application, the diagnostic and predictive segment dominated the market in 2020 and the prognostic segment is expected to experience the fastest CAGR during the forecast period owing to increasing collaborations and efforts to advance diagnostics.
  • Hospitals and clinics segment dominated the market in 2020
  • Medical Laboratories and Diagnostic Centers segment is expected to experience the fastest CAGR during the forecast period due to an increase in testing based on platforms such as NGS and PCR

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends and Scope
3.1 Parents’ Market Outlook
3.2 Mapping of penetration and growth prospects
3.3 Regulatory and reimbursement framework
3.4 Market dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing incidence of breast cancer
3.4.1.2 Technological advances
3.4.1.3 Favorable reimbursement framework for the diagnosis of breast cancer
3.4.1.4 Early detection and increased awareness of breast cancer
3.4.2 Analysis of market restrictions
3.4.2.1 Adverse effects of screening procedures
3.5 Breast Cancer Diagnostics Market Analysis Tools
3.5.1 Pestel analysis
3.5.2 Industry Analysis – Porter’s

Chapter 4 Breast Cancer Diagnostics Market: Type Segment Analysis
4.1 Breast Cancer Diagnostics Market: Type Movements Analysis
4.2 Imaging
4.2.1 Imaging Market, 2017-2028 (USD Million)
4.3 Biopsy
4.3.1 Biopsy Market, 2017 – 2028 (USD Million)
4.4 Genomic tests
4.4.1 Genomic Testing Market, 2017 – 2028 (USD Million)
4.5 Blood tests
4.5.1 Blood Testing Market, 2017 – 2028 (USD Million)
4.6 Others
4.6.1 Others Market, 2017 – 2028 (USD Million)

Chapter 5 Breast Cancer Diagnostics Market: Product Segment Analysis
5.1 Breast Cancer Diagnostics Market: Product Movement Analysis
5.2 Platform-based products
5.2.1 Platform Based Products Market, 2017-2028 (USD Million)
5.2.2 Next-generation sequencing
5.2.2.1 Next Generation Sequencing Market, 2017-2028 (USD Million)
5.2.3 Microarrays
5.2.3.1 DNA Chip Market, 2017-2028 (USD Million)
5.2.4 PCR
5.2.4.1 PCR Market, 2017 – 2028 (USD Million)
5.2.5 Others
5.2.5.1 Other Markets, 2017 – 2028 (USD million)
5.3 Instrumented products
5.3.1 Instrument-Based Products Market, 2017-2028 (USD Million)
5.3.2 Imaging
5.3.2.1 Imaging Market, 2017-2028 (USD Million)
5.3.3 Biopsy
5.3.3.1 Biopsy Market, 2017-2028 (USD Million)

Chapter 6 Breast Cancer Diagnostics Market: Application Segment Analysis
6.1 Breast Cancer Diagnostics Market: Application Movement Analysis
6.2 Screening
6.2.1 Screening Market, 2017-2028 (USD Million)
6.3 Diagnostic & Predictive
6.3.1 Diagnostic and Predictive Market, 2017-2028 (USD Million)
6.4 Prognosis
6.4.1 Forecast market, 2017 – 2028 (USD million)
6.5 Research
6.5.1 Research Market, 2017-2028 (USD Million)

Chapter 7 Breast Cancer Diagnostics Market: End Use Segment Analysis
7.1 Breast Cancer Diagnostics Market: Analysis of End-Use Movements
7.2 Hospitals and clinics
7.2.1 Hospital and Clinic Market, 2017-2028 (USD Million)
7.3 Diagnostic centers and medical laboratories
7.3.1 Diagnostic Center and Medical Laboratory Market, 2017-2028 (USD Million)
7.4 Others
7.4.1 Others Market, 2017-2028 (USD Million)

Chapter 8 Breast Cancer Diagnostics Market: Segment Analysis, by Region, 2017-2028 (USD Million)

Chapter 9 Breast Cancer Diagnostics Market: Competitive Analysis
9.1 Recent Developments and Impact Analysis, by Major Market Players
9.1.1 Ansoff matrix
9.2 Categorization of companies
9.2.1 Innovators
9.2.2 Market leaders
9.3 Supplier landscape
9.3.1 List of major distributors and distribution partners
9.3.2 Key Customers
9.3.3 Key Companies Market Share Analysis, 2020
9.4 Public enterprises
9.4.1 Analysis of the company’s position on the market
9.4.2 Competitive Dashboard Analysis
9.4.2.1 Market differentiators
9.5 Private companies
9.5.1 List of Main Emerging Companies
9.6 Analysis of major transactions and strategic alliances
9.6.1 New product launches
9.6.2 Joint ventures
9.6.3 Acquisition
9.6.4 Licenses and partnerships
9.6.5 Conferences and campaigns
9.7 Company profiles
9.7.1 KONINKLIJKE PHILIPS SA
9.7.1.1 Company overview
9.7.1.2 Financial performance
9.7.1.3 Product Benchmarking
9.7.1.4 Strategic initiatives
9.7.2 DANAHER COMPANY
9.7.2.1 Company overview
9.7.2.2 Financial performance
9.7.2.3 Product Benchmarking
9.7.2.4 Strategic initiatives
9.7.3 HOLOGIC INC
9.7.3.1 Company overview
9.7.3.2 Financial performance
9.7.3.3 Product Benchmarking
9.7.3.4 Strategic initiatives
9.7.4 BECTON, DICKINSON AND COMPANY
9.7.4.1 Company overview
9.7.4.2 Financial performance
9.7.4.3 Product Benchmarking
9.7.4.4 Strategic initiatives
9.7.5 QIAGEN
9.7.5.1 Company overview
9.7.5.2 Financial performance
9.7.5.3 Product Benchmarking
9.7.5.4 Strategic initiatives
9.7.6 THERMO FISHER SCIENTIFIC, INC.
9.7.6.1 Company overview
9.7.6.2 Financial performance
9.7.6.3 Product Benchmarking
9.7.6.4 Strategic initiatives
9.7.7 GENOMIC HEALTH (EXACT SCIENCES)
9.7.7.1 Company overview
9.7.7.2 Financial performance
9.7.7.3 Product Benchmarking
9.7.7.4 Strategic initiatives
9.7.8 MYRIAD GENETICS, INC.
9.7.8.1 Company overview
9.7.8.2 Financial performance
9.7.8.3 Product Benchmarking
9.7.8.4 Strategic initiatives
9.7.9 ARGON MEDICAL DEVICES INC.
9.7.9.1 Company overview
9.7.9.2 Product Benchmarking
9.7.9.3 Strategic initiatives
9.7.10 F. HOFFMANN-LA ROCHE SA
9.7.10.1 Company overview
9.7.10.2 Financial performance
9.7.10.3 Product Benchmarking
9.7.10.4 Strategic initiatives

For more information on this report, visit https://www.researchandmarkets.com/r/p6ntfy

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com

Source link

About Warren Dockery

Check Also

Liquid Crafts Dragon and Bourbon NFTs will launch on October 29

Today the official launch date has been announced for the release of the Liquid Crafts …

Leave a Reply

Your email address will not be published. Required fields are marked *